(Q35034559)

5 August 2017

title

Trastuzumab beyond progression in HER2-positive advanced breast cancer: the Royal Marsden experience (English)

1 reference

5 August 2017

1 reference

T Waddell

1

1 reference

5 August 2017

A Kotsori

2

1 reference

5 August 2017

A Constantinidou

3

1 reference

5 August 2017

N Yousaf

4

1 reference

5 August 2017

S Ashley

5

1 reference

5 August 2017

M Parton

6

1 reference

5 August 2017

M Allen

7

1 reference

5 August 2017

N Starling

8

1 reference

5 August 2017

P Papadopoulos

9

1 reference

5 August 2017

M O'Brien

10

1 reference

5 August 2017

I Smith

11

1 reference

5 August 2017

S Johnston

12

1 reference

5 August 2017

language of work or name

English

0 references

publication date

26 April 2011

1 reference

British Journal of Cancer

5 August 2017

published in

1 reference

5 August 2017

volume

104

1 reference

5 August 2017

issue

11

1 reference

5 August 2017

page(s)

1675-1679

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.2011.138

5 August 2017

exact match

0 references

cites work

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111155

Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111155

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111155

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111155

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111155

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111155

Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111155

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111155

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111155

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111155

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111155

p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111155

Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.

8 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.138

Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.138

Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.138

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.138

Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC)

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21522147

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/BJC.2011.138

1 reference

Dimensions Publication ID

5 August 2017

0 references

1 reference

5 August 2017

1 reference